tiprankstipranks
Market News

IDEXX Laboratories Q3 Earnings and Revenue Top Estimates; Issues Guidance

IDEXX Laboratories, Inc. (IDXX) delivered better-than-expected Q3 2021 results that affirm the impact of ongoing investments in innovation and global commercial capability. Revenue and earnings topped consensus estimates. Nonetheless, IDXX shares fell 5.87% to close at $627.35 on November 2.

IDEXX Laboratories is a U.S.-based company that develops, manufactures, and distributes products and services for animal veterinary. It operates through the Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

The company achieved third-quarter revenue of $810 million, representing 12% year-over-year growth, and above consensus estimates of $798.16 million. The increase was mostly driven by a Companion Animal Group Diagnostics recurring revenue growth of 13%, or 11% organic growth.

Diluted EPS landed at $2.03, exceeding consensus estimates of $1.91. Q3 EPS was supported by operating margin gains of 410 basis points and $0.05 per share in tax benefits and share-based compensation. (See Top Smart Score Stocks on TipRanks)

During the quarter, IDEXX Laboratories integrated its ezyVet acquisition, thus growing its capabilities in cloud-based software. The company also grew its segments of recurring software and diagnostics imaging services.

Additionally, the company remains well-positioned to build on the Q3 success to drive advancement of the standard of healthcare for a companion animal.

For the full year, IDEXX Laboratories is projecting revenue of between $3.19 billion and $3.2 billion, representing 17.5% to 18% growth. Organic growth is projected to range between 15.5% and 16%. EPS, on the other hand, is expected to range between $8.30 and $8.38.

In August, Credit Suisse analyst Katie Tryhane reiterated a Buy rating on the stock and raised the price target to $770 from $735, implying 22.74% upside potential to current levels. The analyst remains confident about the company’s growth trajectory and leadership positioning.

Consensus among analysts is a Moderate Buy based on 1 Buy and 1 Hold. The average IDEXX Laboratories price target of $690 implies a 9.99% upside potential to current levels.

Related News:
Lightspeed to Expand Footprint in Australia and the U.S.
Bausch Health Q3 Profit Rises, Shares Dip
Estée Lauder Raises Quarterly Dividend by 13%

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More